过继输注体外激活的免疫效应细胞以介导体内肿瘤消退或缓解是现代免疫学在肿瘤治疗研究中的重要进展之一。然而 ,迄今有关临床观察表明其作用有限 ,究其原因 ,认为效应细胞不能迁移至靶器官是影响治疗效果的重要因素之一[1] 。本研究皆在探讨ＣＤ3ＡＫ细胞不同途径输注时的体内 Adoptive infusion of in vitro activated immune effector cells to mediate tumor regression or mitigation is one of the important advances in modern immunology in cancer therapy research. However, clinical observations so far have shown limited effects. The reason for this is that it is one of the important factors affecting the therapeutic effect that effector cells cannot migrate to the target organ [1]. This study was to investigate the in vivo infusion of different pathways of CD3AK cells.